Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT03176381

Sponsor: Tianjin Medical University Second Hospital



  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  1. Participants who have given consent form;
  2. Patients with a confirmed diagnosis of mCRPC according to EAU 2017 guideline;
  3. Serum testosterone must reach castration level: <50 ng per deciliter;
  4. Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment.

Exclusion Criteria:

  1. Participants who are allergic to contrast medium;
  2. Patients were excluded if they planned to receive additional concurrent anticancer therapies;
  3. Patients doesn't sign an informed consent form.

View trial on